Cargando…

Sandostatin therapy in patients with chronic sarcoidosis

Detalles Bibliográficos
Autores principales:	Timmermans, Wilhelmina M.C., van Laar, Jan A.M., Dalm, Virgil A.S.H., Kam, Boen L.R., van Hagen, P. Martin, van Daele, Paul L.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170097/ https://www.ncbi.nlm.nih.gov/pubmed/32476857 http://dx.doi.org/10.36141/svdld.v34i3.6143

Ejemplares similares

Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis
por: Eurelings, Laura E. M., et al.
Publicado: (2019)

Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment
por: Both, Tim, et al.
Publicado: (2017)

Somatostatin receptor scintigraphy in sarcoidosis
por: Kamphuis, Lieke SJ, et al.
Publicado: (2011)

Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department
por: Guchelaar, Niels A.D., et al.
Publicado: (2021)

Everything you need to know about distal renal tubular acidosis in autoimmune disease
por: Both, Tim, et al.
Publicado: (2014)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Immunopathogenesis of granulomas in chronic autoinflammatory diseases
por: Timmermans, Wilhelmina Maria Cornelia, et al.
Publicado: (2016)

Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin.
por: Nelson, J., et al.
Publicado: (1989)

Do synovial biopsies help to support evidence for involvement of innate immunity in the immunopathology of Behçet's disease?
por: van Laar, Jan AM, et al.
Publicado: (2009)

Managing Behçet’s disease: An update on current and emerging treatment options
por: van Daele, P LA, et al.
Publicado: (2009)

Infliximab treatment in pathology-confirmed neurosarcoidosis
por: Fritz, Daan, et al.
Publicado: (2020)

Bone Mineral Density in Sjögren Syndrome Patients with and Without Distal Renal Tubular Acidosis
por: Both, Tim, et al.
Publicado: (2016)

Psychological Symptoms in Primary Immunodeficiencies: a Common Comorbidity?
por: Manusama, Olivia R., et al.
Publicado: (2022)

Basophil Activation Test in the prediction of anaphylactic reactions against Hymenoptera venom in patients suffering from Systemic Mastocytosis
por: Rietveld, Mark JA, et al.
Publicado: (2012)

Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
por: Petersen, Holger, et al.
Publicado: (2011)

Soluble Interleukin-2 Receptor/White Blood Cell Ratio Reflects Granulomatous Disease Progression in Common Variable Immune Deficiency
por: van Stigt, Astrid C., et al.
Publicado: (2023)

Macrophage-fibroblast interplay: a target for neuropeptide-based treatment of fibrotic disease?
por: Virakul, Sita, et al.
Publicado: (2012)

Octreotida (sandostatin) mas tratamiento convencional en la diarrea refractaria del SIDA.
por: Rosado Castellanos, Marcos Antonio
Publicado: (1995)

The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases.
por: Hemingway, D. M., et al.
Publicado: (1992)

Diagnostic Performance of Electronic Nose Technology in Sarcoidosis
por: van der Sar, Iris G., et al.
Publicado: (2022)

Distal renal tubular acidosis in primary Sjögren syndrome
por: Both, Tim, et al.
Publicado: (2012)

Soluble Interleukin-2 Receptor Is a Promising Serum Biomarker for Granulomatous Disease in Common Variable Immune Deficiency
por: van Stigt, Astrid C., et al.
Publicado: (2021)

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
por: Klijn, J. G., et al.
Publicado: (1990)

Amelioration of Symptoms and Reduction of VIP Levels after Hepatic Artery Chemoembolization in a Patient with Sandostatin Resistant VIPoma
por: Shaib, Walid, et al.
Publicado: (2010)

A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
por: Hrachova, Maya, et al.
Publicado: (2020)

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners
por: Moor, C. C., et al.
Publicado: (2018)

A CDC42 Stop-loss Mutation in a Patient with Relapsing Polychondritis and Autoinflammation
por: van Wijck, Rogier T. A., et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis in Activated PI3K Delta Syndrome: an Illustrative Case Report
por: Zhou, Zijun, et al.
Publicado: (2021)

Cytokines in the colon of a patient with Behçet's disease
por: Kappen, Jasper H, et al.
Publicado: (2009)

Chronically Activated T-cells Retain Their Inflammatory Properties in Common Variable Immunodeficiency
por: Berbers, Roos-Marijn, et al.
Publicado: (2021)

Three patients with defects in interferon gamma receptor signaling: A challenging diagnosis
por: Zhou, Zijun, et al.
Publicado: (2022)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

SAT-432 MTD201 Has a Favourable 28-Day Sustained Release Profile Compared to Sandostatin LAR in Healthy Subjects
por: Seaman, Paul, et al.
Publicado: (2019)

The 11q Terminal Deletion Disorder Jacobsen Syndrome is a Syndromic Primary Immunodeficiency
por: Dalm, Virgil A. S. H., et al.
Publicado: (2015)

Targeted Proteomics Reveals Inflammatory Pathways that Classify Immune Dysregulation in Common Variable Immunodeficiency
por: Berbers, Roos-Marijn, et al.
Publicado: (2020)

T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?
por: Brkic, Zana, et al.
Publicado: (2014)

A Novel Heterozygous Mutation in the STAT1 SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation
por: Meesilpavikkai, Kornvalee, et al.
Publicado: (2017)

Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade(®) to Remsima(®)? An Observational Study
por: Xue, Laixi, et al.
Publicado: (2020)

Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression
por: Brkic, Zana, et al.
Publicado: (2013)

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren's syndrome
por: Maria, Naomi I, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bsi9ggjati009dqi7a0ua1me8e